- Category
- Medium (2024-25)
- Udyam number
- UDYAM-DL-02-0013095

About Obsurge Biotech Limited
Data last updated:
Obsurge Biotech Limited is a public limited company based in Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 04 January 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2002PLC113701. Its GSTIN is 07AAACO5037A2ZY (Delhi). The company holds 5 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹30 Lakh and a paid-up capital of ₹28.15 Lakh. It is led by directors including Avijit Chauhan (Managing Director) and Latish Malhotra (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 101 – 102 Aditya Tower District Centre Laxmi Nagar, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹72.73 Cr, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹6.25 Cr (net margin 8.6%) and EBITDA of ₹9.22 Cr (EBITDA margin 12.7%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 10% over five years.
The company has about 606 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Obsurge Biotech. As per MCA filings, the company has open charges of ₹25.88 Lakh and satisfied charges of ₹5.02 Cr on record. Court records list 23 cases involving the company, including 15 filed by the company and 8 filed against it; 2 cases are pending. The company has 5 deals on record (4 secondary share transfers, 1 funding round), with disclosed funding of ₹10 Lakh; the latest was in March 2016. Its 8 peer companies in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading) are compared by revenue, 5 larger and 3 smaller; the largest is Venkatasai Agencies Hyd Private Limited with revenue of ₹73.45 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 49 overdue payments to 30 micro and small suppliers.
Obsurge Biotech Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-02-0013095). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website obsurge.com.
Company details
Recognitions & Rankings of Obsurge Biotech
Contact details
Obsurge Biotech Limited's registered office is in Delhi, Delhi. Its website is obsurge.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address101 – 102 Aditya Tower District Centre Laxmi Nagar, Delhi, India – 110092
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Obsurge Biotech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Obsurge Biotech operates one associated brand: Obsurge Biotech. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Develops and manufactures healthcare products focused on cardiology, dentistry, and other therapeutic areas. | obsurge.com |
Business activity
The main business activity of Obsurge Biotech is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Obsurge Biotech Limited, buy the company report.
Financials of Obsurge Biotech Limited
FY 2024 filings availableObsurge Biotech Limited reported revenue of ₹72.73 Cr (up 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 10% over five years, including 8% growth in the latest year. EBITDA fell 11% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹9.22 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹6.25 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 12.7% | ||||
| Net Profit Margin | 8.6% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Obsurge Biotech Limited, buy the company report.
Board of directors of Obsurge Biotech Limited
Obsurge Biotech has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Avijit Chauhan Also directs: Smartcity Distributors LLP | Managing Director | 07 Jan 2008 | 18 Years 9 Months | Current |
| Amin Ul Aziz Also directs: Bhujadhari Vincom Private Limited, F & S Trading Private Limited, Rosebud Tradelink Private Limited and 2 more | Director | 03 Apr 2015 | 11 Years 6 Months | Current |
| Jaswant Singh Chauhan | Director | 04 Jan 2002 | 24 Years 9 Months | Current |
| Latish Malhotra Also directs: Jagdish Medicare Private Limited | Whole-Time Director | 04 Jan 2002 | 24 Years 9 Months | Current |
Peer comparison
Obsurge Biotech Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Venkatasai Agencies Hyd Private Limited | ₹73.45 Cr (FY 2023) | -5.0% | Hyderabad, Telangana, India | |||
| Nidhi Associates Private Limited | ₹73.36 Cr (FY 2024) | 13.0% | New Delhi, Delhi, India | |||
| Aastrid International Private Limited | ₹72.84 Cr (FY 2025) | 11.0% | Mumbai, Maharashtra, India | |||
| NV Remedies Private Limited | ₹72.84 Cr (FY 2025) | 78.0% | Navi Mumbai, Maharashtra, India | |||
| Anila Medical Private Limited | ₹72.79 Cr (FY 2025) | 40.0% | Indore, Madhya Pradesh, India | |||
| Obsurge Biotech Limitedthis company | ₹72.73 Cr (FY 2025) | ₹6.25 Cr | 8.6% | 8.0% | 606 | Delhi, India |
| Sweta Distributors Private Limited | ₹72.34 Cr (FY 2025) | 18.0% | Thane, Maharashtra, India | |||
| Makers Pharma Private Limited | ₹72.25 Cr (FY 2022) | 72.0% | Chennai, Tamil Nadu, India | |||
| Arinna Lifesciences Limited | ₹72.24 Cr (FY 2025) | 10.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Obsurge Biotech Limited, buy the company report.
Auditor
Obsurge Biotech Limited is audited by VBR & ASSOCIATES for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VBR & ASSOCIATES | FY 2024 | 013174N |
Shareholding
The shareholding of Obsurge Biotech Limited is on record for 3 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Obsurge Biotech Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Mar 2022 | 100565326 | Hdfc Bank Limited | ₹25.88 Lakh | Open | |
| 30 May 2018 | 100202488 | Hdfc Bank Limited | ₹2 Cr | Satisfied | |
| 28 Feb 2013 | 10413658 | Citibank N.A | ₹1.5 Cr | Satisfied | |
| 02 Sep 2002 | 80018193 | Union Bank of India | ₹1.52 Cr | Satisfied |
To see the full charge records of Obsurge Biotech Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Obsurge Biotech Limited has 5 deals on record (4 secondary share transfers, 1 funding round), with disclosed funding of ₹10 Lakh; the latest was in March 2016.
Deals on record (5 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: Jaswant Singh Chauhan Huf Seller: an individual |
| Jan 2010 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Jan 2008 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Apr 2007 | Funding round | ₹10 Lakh | Investors: an individual |
| Mar 2006 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 4 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Obsurge Biotech Limited has 23 court cases on record: 15 filed by Obsurge Biotech, 8 filed against it. 2 cases are pending and 21 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 13 | 0 | 0 |
| District courts | 9 | 7 | 2 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 23)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (CS(OS)) | Filed by the company against M/S Goodman Gilmans Life Sciences Pvt Ltd & Anr | Disposed |
| District court, East, Delhi | Cheque dishonour complaint | Filed by the company against M/S Shikha Drug Distributor | Pending |
| District court, North West, Delhi | Criminal case | Filed by the company against Chitra Pharmaceutical and Ors. | Pending |
| District court, Central, Delhi | Court case (L I R) | Filed against the company by an individual | Disposed |
| District court, South West, Delhi | Civil suit | Filed against the company by State | Disposed |
To see the full case history of Obsurge Biotech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Obsurge Biotech Limited has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 49 overdue payments to 30 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 30)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Needs | |||
| Essen Medicare LLP | |||
| Medicine Agencies | |||
| an individual supplier | |||
| Global Pharmaceuticals |
To see the full MSME payment records of Obsurge Biotech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Obsurge Biotech Limited has a workforce of 606 employees on its EPFO records as of Sep 22, 2025, across 1 active EPFO establishment.
GST
Obsurge Biotech has 5 GST registrations: 4 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACO5037A2ZY | Delhi | Active | 12 Jul 2017 |
| 09AAACO5037A1ZV | Uttar Pradesh | Active | 01 Jul 2017 |
| 06AAACO5037A1Z1 | Haryana | Active | 14 Jul 2021 |
| 18AAACO5037A1ZW | Assam | Active | 09 Mar 2022 |
To see the full GST registrations and return filing status of Obsurge Biotech Limited, buy the company report.
Recent activity
Obsurge Biotech Limited has 8 board changes on record since 2002: 4 appointments and 4 cessations. The latest: Avijit Chauhan ceased to be Whole-Time Director on 01 Apr 2021.
7 earlier events are in the company report.
Frequently asked questions
Obsurge Biotech is an active public limited company based in Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 04 January 2002 (24+ years old) and is registered under CIN U24232DL2002PLC113701.
Obsurge Biotech has 4 current directors:
- Avijit Chauhan - Managing Director
- Latish Malhotra - Whole-Time Director
- Amin Ul Aziz - Director
- Jaswant Singh Chauhan - Director
The latest financial statements of Obsurge Biotech on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Obsurge Biotech is 07AAACO5037A2ZY, registered in Delhi. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 09AAACO5037A1ZV (Uttar Pradesh), 06AAACO5037A1Z1 (Haryana), 18AAACO5037A1ZW (Assam).
The CIN (Corporate Identification Number) of Obsurge Biotech is U24232DL2002PLC113701. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Obsurge Biotech has 23 court cases on record: 15 filed by the company and 8 filed against it. 2 are pending. Most are in the high courts.
Obsurge Biotech was incorporated on 04 January 2002, making it 24+ years old. It is registered with the Registrar of Companies, Delhi.
Obsurge Biotech has 5 deals on record (4 secondary share transfers, 1 funding round), with disclosed funding of ₹10 Lakh; the latest was in March 2016.
The peers of Obsurge Biotech by revenue are Venkatasai Agencies Hyd Private Limited, Nidhi Associates Private Limited, Aastrid International Private Limited, NV Remedies Private Limited, Anila Medical Private Limited and 3 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Avijit Chauhan ceased to be Whole-Time Director on 01 Apr 2021. Jaswant Singh Chauhan ceased to be Managing Director on 31 Mar 2021. Amin Ul Aziz ceased to be Additional Director on 30 Sep 2015. Obsurge Biotech has 8 board changes on record in total.
Yes, Obsurge Biotech is registered as a medium enterprise under Udyam registration (number: UDYAM-DL-02-0013095).
Obsurge Biotech has 1 MSME Form 1 return on record for the period ending Mar 2024, listing 49 overdue payments to 30 micro and small suppliers. The latest return was filed on 30 Apr 2024.